Ribavirin: all 452 studies that test it

Page 2 of 5. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Study in Subjects With Chronic HCV and Underlying HemophiliaCompletedNCT01741545Phase 3Results posted
• Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2CompletedNCT01728324Phase 3Results posted
• HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedNCT01718301Phase 3Results posted
• A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)CompletedNCT01717326Phase 2Results posted
• A Study to Evaluate Chronic Hepatitis C InfectionCompletedNCT01716585Phase 3Results posted
• A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)CompletedNCT01716156Phase 2Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced AdultsCompletedNCT01715415Phase 3Results posted
• Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) InfectionCompletedNCT01713283Phase 2Results posted
• A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)CompletedNCT01710501Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated CirrhosisCompletedNCT01704755Phase 3Results posted
• An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C VirusTerminatedNCT01701063Phase 1/2Results posted
• Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b ParticipantsCompletedNCT01700179Phase 1Results posted
• Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)CompletedNCT01678131Phase 1Results posted
• A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis CCompletedNCT01674725Phase 3Results posted
• Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusCompletedNCT01628692Phase 2Results posted
• A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination StudyCompletedNCT01609933Phase 2Results posted
• Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)TerminatedNCT01606800Phase 4Results posted
• Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant RecipientsTerminatedNCT01592006Phase 4Results posted
• A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)CompletedNCT01585324Phase 4Results posted
• Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-TransplantCompletedNCT01559844Phase 2Results posted
• Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)CompletedNCT01544920Phase 3Results posted
• This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedNCT01528735Phase 2Results posted
• Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedNCT01525628Phase 1Results posted
• Respiratory Syncytial Virus - RSV ProtocolCompletedNCT01502072Phase 2Results posted
• Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CTerminatedNCT01500772Phase 3Results posted
• Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01498068Phase 3Results posted
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV InfectionCompletedNCT01482767Phase 3Results posted
• A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1CompletedNCT01479868Phase 3Results posted
• Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV VirusCompletedNCT01471574Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedNCT01468584Phase 3Results posted
• An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant PatientsTerminatedNCT01467505Phase 2Results posted
• Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
• A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)TerminatedNCT01467479Phase 3Results posted
• A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive PatientsCompletedNCT01466790Phase 2Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedNCT01466192Phase 3Results posted
• ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected PatientsCompletedNCT01464827Phase 2Results posted
• Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
• A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)CompletedNCT01458535Phase 2Results posted
• Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIVTerminatedNCT01443923Phase 4Results posted
• GS-7977 With Ribavirin for Hepatitis C (SPARE)CompletedNCT01441180Phase 1/2Results posted
• Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C SubjectsCompletedNCT01439373Phase 2Results posted
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedNCT01428063Phase 2Results posted
• Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)CompletedNCT01405937Phase 3Results posted
• Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)CompletedNCT01405560Phase 3Results posted
• BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis CCompletedNCT01389323Phase 3Results posted
• A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01366638Phase 3Results posted
• A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3CompletedNCT01364090Phase 4Results posted
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCompletedNCT01359644Phase 2Results posted
• A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedNCT01330316Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT01306617Phase 2Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedNCT01297270Phase 3Results posted
• A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based TherapyCompletedNCT01290731Phase 3Results posted
• A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based TherapyCompletedNCT01288209Phase 3Results posted
• Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell CarcinomaCompletedNCT01268579Not applicableResults posted
• Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3CompletedNCT01260350Phase 2Results posted
• A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3CompletedNCT01258101Phase 4Results posted
• VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT01241760Phase 3Results posted
• Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for ComplicationsCompletedNCT01227967Phase 2Results posted
• A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)CompletedNCT01221298Phase 2Results posted
• Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve ParticipantsCompletedNCT01215643Phase 2Results posted
• A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment FailuresCompletedNCT01185028Phase 1/2Results posted
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous TreatmentCompletedNCT01183169Phase 2Results posted
• Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedNCT01132313Phase 2Results posted
• Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01097395Phase 4Results posted
• Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid LeukemiaCompletedNCT01056523Phase 1/2Results posted
• VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir PlaceboCompletedNCT01054573Phase 3Results posted
• Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin TreatmentCompletedNCT01052701Phase 1Results posted
• Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-RespondersCompletedNCT01051921Phase 2Results posted
• A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow ResponseCompletedNCT01033448Phase 4Results posted
• Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected SubjectsCompletedNCT00991289Phase 2Results posted
• Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)CompletedNCT00984620Phase 2Results posted
• Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIVCompletedNCT00983853Phase 2Results posted
• The Raltegravir and Ribavirin Pharmacokinetics (PK) StudyCompletedNCT00982553Phase 1Results posted
• A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard TreatmentCompletedNCT00980330Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) PatientsCompletedNCT00947349Phase 2Results posted
• A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis CCompletedNCT00922779Phase 4Results posted
• Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)CompletedNCT00910624Phase 3Results posted
• Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)CompletedNCT00892697Phase 2Results posted
• Treatment of Acute Hepatitis C Virus in HIV Co-InfectionCompletedNCT00845676Phase 4Results posted
• Ribavirin 200 mg Tablets Under Non-Fasting ConditionsCompletedNCT00835536Phase 1Results posted
• Ribavirin 200 mg Tablets Under Fasting ConditionsCompletedNCT00835146Phase 1Results posted
• A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner ProtocolsCompletedNCT00800735Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based TherapyCompletedNCT00781274Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyCompletedNCT00780910Phase 3Results posted
• 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)CompletedNCT00761735Phase 3Results posted
• A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedNCT00758043Phase 3Results posted
• High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1CompletedNCT00735969Phase 2Results posted
• Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)TerminatedNCT00687544Phase 4Results posted
• Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)CompletedNCT00687219Phase 3Results posted
• Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)CompletedNCT00686777Phase 4Results posted
• Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)CompletedNCT00686517Phase 3Results posted
• Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin ResistanceCompletedNCT00665353Phase 2Results posted
• A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis CCompletedNCT00630058Phase 1Results posted
• A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral ResponseCompletedNCT00623428Phase 3Results posted
• A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard TreatmentCompletedNCT00537407Phase 2Results posted
• A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to TherapyCompletedNCT00535847Phase 2Results posted
• An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C ParticipantsCompletedNCT00528528Phase 2Results posted
• Intermittent Use of Aerosolized Ribavirin for Treatment of RSVCompletedNCT00500578Phase 4Results posted
• Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected PatientsCompletedNCT00495131Phase 4Results posted
• Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis CCompletedNCT00491244Phase 4Results posted

← Ribavirin overview